ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2016-06-21

Last Posted Date: 2019-01-25

Lead Sponsor: AbbVie

Target Recruit Count: 522

Registration Number: NCT02807402

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

Phase 3

Withdrawn

Conditions: Chronic Hepatitis C Virus

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir

First Posted Date: 2016-06-20

Last Posted Date: 2016-12-05

Lead Sponsor: AbbVie

Registration Number: NCT02806362

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin
Behavioral: Patient support program

First Posted Date: 2016-06-16

Last Posted Date: 2019-10-11

Lead Sponsor: AbbVie

Target Recruit Count: 256

Registration Number: NCT02803138

Locations: 🇮🇱
Ha'Emek Medical Center /ID# 153695, Afula, Israel
🇮🇱
Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel
🇮🇱
The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel

and more 15 locations

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2016-06-14

Last Posted Date: 2018-12-31

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT02798315

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Phase 3

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: Optimized antiparkinsonian treatment
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
Device: CADD-Legacy ambulatory infusion pump
Device: Percutaneous endoscopic gastrostomy tube
Device: Jejunal extension tube

First Posted Date: 2016-06-14

Last Posted Date: 2020-08-18

Lead Sponsor: AbbVie

Target Recruit Count: 63

Registration Number: NCT02799381

Locations: 🇫🇮
Oulun yliopistollinen sairaala /ID# 150947, Oulu, Finland
🇮🇹
A.O. Univ. Ospedali Riuniti /ID# 150853, Ancona, Marche, Italy
🇮🇹
Policlinico Universitario Campus Bio-Medico /ID# 150846, Rome, Lazio, Italy

and more 25 locations

Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting

Completed

Conditions: Hidradenitis Suppurativa

First Posted Date: 2016-06-01

Last Posted Date: 2020-01-09

Lead Sponsor: AbbVie

Target Recruit Count: 236

Registration Number: NCT02786576

Locations: 🇧🇪
Meuleman, Lede, BE /ID# 154238, Lede, Belgium
🇨🇿
Vojenska nemocnice /ID# 163592, Olomouc, Czechia
🇨🇿
Kozni sanatorium /ID# 163591, Praha, Czechia

and more 80 locations

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Withdrawn

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2016-06-01

Last Posted Date: 2018-11-26

Lead Sponsor: AbbVie

Registration Number: NCT02786563

Locations: 🇨🇳
Peking University Peoples Hospit /ID# 148961, Beijing, Beijing, China
🇨🇳
Xijing Hospital /ID# 148960, Xian, Shaanxi, China
🇨🇳
Renji Hosp, Shanghai Jiaotong /ID# 148959, Shanghai, China

and more 1 locations

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Phase 2

Active, not recruiting

Conditions: Crohn's Disease (CD)

Interventions: Drug: ABT-494

First Posted Date: 2016-05-25

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 107

Registration Number: NCT02782663

Locations: 🇺🇸
Virginia Mason Hospital & Medical Center /ID# 150042, Seattle, Washington, United States
🇺🇸
University of Washington /ID# 149988, Seattle, Washington, United States
🇺🇸
Duplicate_University of Florida - Archer /ID# 150033, Gainesville, Florida, United States

and more 58 locations

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Caffeine
Drug: Warfarin
Drug: Omeprazole
Drug: Metoprolol
Drug: Midazolam
Drug: Risankizumab

First Posted Date: 2016-05-13

Last Posted Date: 2017-09-25

Lead Sponsor: AbbVie

Target Recruit Count: 21

Registration Number: NCT02772601

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Venetoclax

First Posted Date: 2016-04-29

Last Posted Date: 2023-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 258

Registration Number: NCT02756611

Locations: 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 147462, Toronto, Ontario, Canada
🇵🇹
IPO Porto FG, EPE /ID# 147389, Porto, Portugal
🇨🇭
Hopitaux Universitaires de Geneve /ID# 147930, Genève, Geneve, Switzerland

and more 64 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy